Clicky

Axonics Inc(0I3)

Description: Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California. As of November 15, 2024, Axonics, Inc. operates as a subsidiary of Boston Scientific Corporation.


Keywords: Medical Technology Neurotechnology Neuromodulation Urinary Incontinence Overactive Bladder Continence Urinary System Incontinence Fecal Incontinence

Home Page: www.axonics.com

26 Technology Drive
Irvine, CA 92618
United States
Phone: 949 396 6322


Officers

Name Title
Mr. Raymond W. Cohen CEO & Director
Ms. Kari Keese Chief Financial Officer
Mr. Rinda K. Sama Chief Operating Officer
Dr. John Woock Ph.D. Executive VP, Chief Marketing & Strategy Officer
Mr. Alfred J. Ford Jr. Chief Commercial Officer
Mr. Guangqiang Jiang Ph.D. Chief Technology Officer
Mr. Neil Bhalodkar Vice President of Investor Relations
Mr. Aaron Pettit General Counsel & Chief Compliance Officer
Mr. Michael V. Williamson Esq., J.D. Senior VP, General & IP Counsel
Dr. Karen L. Noblett M.A.S., M.D. Chief Medical Officer

Exchange: F

Country: DE : Germany

Currency: Euro (€)

Forward PE: 100
Trailing PE: 0
Price-to-Book MRQ: 5.1426
Price-to-Sales TTM: 7.8528
IPO Date:
Fiscal Year End: December
Full Time Employees: 797
Back to stocks